Submissions for the 2017 ASCP Annual Meeting are now closed.
The Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP) will be held at the Loews Miami Beach, May 29 – June 3, 2017. The committee welcomed submissions from the U.S. as well as international proposals.
The theme of this year’s meeting is “Serving the Needs of the Diverse Population”.
Panels and Workshops – Chair Overall Deadline: November 7, 2016
Panel and Workshop Presenter: November 17, 2016
New Investigator Awards: January 30, 2017
Posters: January 30, 2017
Individual Research Reports: January 30, 2017
Pharmaceutical Pipeline Presentations: February 13, 2017
Poster Presentation – Poster board presentation in a general session. View submission instructions for Posters Presentations.
Individual Research Report – Selected by the Program Committee, these are 10 minute oral presentation with 5 minutes Q&A from the audience. View submission instructions for Individual Research Reports.
New Investigator Award Program – These travel awards are specifically designed for individuals who are new to the field and have not been the Principal Investigator on an R01 grant. The NIA participant will also have the opportunity to present a poster and/or individual research report presentation. View submission instructions for New Investigator Awardee submissions.
Panel Sessions – Have a Chair, a minimum of 3 Speakers but no more than 4 speakers, and a discussant. A co-chair is optional. Panel sessions are 1.5 hours in length. View submission instructions for Panel Sessions.
Workshop Sessions – Integrative session with a chair and no more than 8 participants. A discussant and co-chair is optional. Workshop sessions are 2 hours in length. View submission instructions for Workshop Sessions.
Pharmaceutical Pipeline Presentations – A Pharmaceutical Pipeline report will be a 10 minute presentation and will also have the opportunity to present their research as a poster presentation. A Pharmaceutical Pipeline submission should include those with early clinical data (Phase 1 and 2) on any CNS compound for which Phase 3 data had not been presented. The goal was to generate enthusiasm for the many novel compounds under exploration, most of which have not reached Phase 3. This is not to exclude presentations of clinical data on compounds currently in Phase 3 targeted to truly untested mechanisms since such data would also be of great interest. View submission instructions for a Pharmaceutical Pipeline Presentation.
All presenters are required to complete an electronic disclosure as part of the submission process for all submission types. Please click HERE for a copy of the disclosure form.